{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:21Z","timestamp":1740107001536,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006244","name":"Stichting Kinderen Kankervrij","doi-asserted-by":"publisher","award":["320","320","320","320","320","320","320","320","320","320"],"award-info":[{"award-number":["320","320","320","320","320","320","320","320","320","320"]}],"id":[{"id":"10.13039\/501100006244","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Chemotherapy-induced nausea and vomiting (CINV) are common side effects in pediatric oncology treatment. Besides 5-HT<jats:sub>3<\/jats:sub>-antagonists, both dexamethasone and aprepitant are cornerstone drugs in controlling these side effects. Based on results of adult studies, the dexamethasone dose is reduced by 50% when combined with aprepitant, because of a drug-drug interaction, even though data on the interaction in children is lacking. The current study was developed to investigate the effect of aprepitant on dexamethasone clearance (CL) in children, in order to assess if dexamethasone dose reduction for concomitant use of aprepitant is appropriate in the current antiemetic regimen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In total, 65 children (0.6\u201317.9\u00a0years), receiving intravenous or oral antiemetic therapy (dexamethasone\u2009\u00b1\u2009aprepitant) as standard of care, were included. 305 dexamethasone plasma concentrations were determined using LC\u2013MS\/MS. An integrated dexamethasone and aprepitant pharmacokinetic model was developed using non-linear mixed effects modelling in order to investigate the effect of aprepitant administration on dexamethasone CL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In this population, dexamethasone CL in patients with concomitant administration of aprepitant was reduced by approximately 30% of the uninhibited CL (23.3 L\/h (95% confidence interval 20.4\u201326.0)). This result is not consistent with the results of adult studies (50% reduction). This difference was not age dependent, but might be related to the route of administration of dexamethasone. Future studies are needed to assess the difference in oral\/intravenous dexamethasone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>When dexamethasone is given intravenously as a component of triple therapy to prevent CINV in children, we advise to reduce the dexamethasone dose by 30% instead of 50%.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-022-07423-6","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T14:02:44Z","timestamp":1666792964000},"page":"9991-9999","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3448-7665","authenticated-orcid":false,"given":"A. Laura","family":"Nijstad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4828-7069","authenticated-orcid":false,"given":"Evelien","family":"de Vos-Kerkhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-0938","authenticated-orcid":false,"given":"Catherine F.","family":"Enters-Weijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4127-3032","authenticated-orcid":false,"given":"Marianne D.","family":"van de Wetering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-507X","authenticated-orcid":false,"given":"Wim J. E.","family":"Tissing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthijs M.","family":"Tibben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3124-692X","authenticated-orcid":false,"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3149-3501","authenticated-orcid":false,"given":"Arief","family":"Lalmohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-4639","authenticated-orcid":false,"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-8268","authenticated-orcid":false,"given":"C. Michel","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"key":"7423_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00520-016-3384-y","volume":"25","author":"LL Dupuis","year":"2017","unstructured":"Dupuis LL, Sung L, Molassiotis A et al (2017) 2016 updated MASCC\/ESMO consensus recommendations: prevention of acute chemotherapy-induced nausea and vomiting in children. Support Care Cancer 25:323\u2013331. https:\/\/doi.org\/10.1007\/s00520-016-3384-y","journal-title":"Support Care Cancer"},{"key":"7423_CR2","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240\u20133261","journal-title":"J Clin Oncol"},{"key":"7423_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pbc.26542","volume":"64","author":"P Patel","year":"2017","unstructured":"Patel P, Robinson PD, Thackray J et al (2017) Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. Pediatr Blood Cancer 64:1\u201312. https:\/\/doi.org\/10.1002\/pbc.26542","journal-title":"Pediatr Blood Cancer"},{"key":"7423_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00520-016-3449-y","volume":"25","author":"LH Einhorn","year":"2017","unstructured":"Einhorn LH, Rapoport B, Navari RM et al (2017) 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25:303\u2013308. https:\/\/doi.org\/10.1007\/s00520-016-3449-y","journal-title":"Support Care Cancer"},{"key":"7423_CR5","doi-asserted-by":"publisher","first-page":"e27646","DOI":"10.1002\/pbc.27646","volume":"66","author":"E Paw Cho Sing","year":"2019","unstructured":"Paw Cho Sing E, Robinson PD, Flank J et al (2019) Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline. Pediatr Blood Cancer 66:e27646. https:\/\/doi.org\/10.1002\/pbc.27646","journal-title":"Pediatr Blood Cancer"},{"key":"7423_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/cpt1975182205","volume":"18","author":"DE Duggan","year":"1975","unstructured":"Duggan DE, Yeh KC, Matalia N et al (1975) Bioavailability of oral dexamethasone. Clin Pharmacol Ther 18:205\u2013209. https:\/\/doi.org\/10.1002\/cpt1975182205","journal-title":"Clin Pharmacol Ther"},{"key":"7423_CR7","unstructured":"Dexcel Pharma Technologies (per FDA) (2019) Product Information: HEMADY(TM) oral tablets, dexamethasone oral tablets. Boulder, CO"},{"key":"7423_CR8","first-page":"329","volume":"3","author":"O Richter","year":"1983","unstructured":"Richter O, Ern B, Reinhardt D, Becker B (1983) Pharmacokinetics of dexamethasone in children. Pediatr Pharmacol (New York) 3:329\u2013337","journal-title":"Pediatr Pharmacol (New York)"},{"key":"7423_CR9","unstructured":"Merck Sharp, Dohme BV (2008) Summary of product characteristics: Emend"},{"key":"7423_CR10","unstructured":"Merck Sharp, Dohme BV (2013) Summary of product characteristics: Ivemend"},{"key":"7423_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0009-9236(03)00066-3","volume":"74","author":"JB McCrea","year":"2003","unstructured":"McCrea JB, Majumdar AK, Goldberg MR et al (2003) Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74:17\u201324. https:\/\/doi.org\/10.1016\/S0009-9236(03)00066-3","journal-title":"Clin Pharmacol Ther"},{"key":"7423_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00280-008-0713-y","volume":"63","author":"S Nakade","year":"2008","unstructured":"Nakade S, Ohno T, Kitagawa J et al (2008) Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol 63:75\u201383. https:\/\/doi.org\/10.1007\/s00280-008-0713-y","journal-title":"Cancer Chemother Pharmacol"},{"key":"7423_CR13","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1177\/0091270010387792","volume":"51","author":"TC Marbury","year":"2011","unstructured":"Marbury TC, Ngo PL, Shadle CR et al (2011) Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J Clin Pharmacol 51:1712\u20131720. https:\/\/doi.org\/10.1177\/0091270010387792","journal-title":"J Clin Pharmacol"},{"key":"7423_CR14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00280-010-1519-2","volume":"68","author":"T Takahashi","year":"2011","unstructured":"Takahashi T, Nakamura Y, Tsuya A et al (2011) Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients. Cancer Chemother Pharmacol 68:653\u2013659. https:\/\/doi.org\/10.1007\/s00280-010-1519-2","journal-title":"Cancer Chemother Pharmacol"},{"key":"7423_CR15","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1093\/annonc\/mdq149","volume":"21","author":"MS Aapro","year":"2010","unstructured":"Aapro MS, Walko CM (2010) Aprepitant: drug\u2013drug interactions in perspective. Ann Oncol 21:2316\u20132323. https:\/\/doi.org\/10.1093\/annonc\/mdq149","journal-title":"Ann Oncol"},{"key":"7423_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/00043426-200003000-00009","volume":"22","author":"BE Small","year":"2000","unstructured":"Small BE, Holdsworth MT, Raisch DW, Winter SS (2000) Survey ranking of emetogenic control in children receiving chemotherapy. J Pediatr Hematol Oncol 22:125\u2013132. https:\/\/doi.org\/10.1097\/00043426-200003000-00009","journal-title":"J Pediatr Hematol Oncol"},{"key":"7423_CR17","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/cncr.21631","volume":"106","author":"MT Holdsworth","year":"2006","unstructured":"Holdsworth MT, Raisch DW, Frost J (2006) Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer 106:931\u2013940. https:\/\/doi.org\/10.1002\/cncr.21631","journal-title":"Cancer"},{"key":"7423_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2165\/11316190-000000000-00000","volume":"12","author":"LL Dupuis","year":"2010","unstructured":"Dupuis LL, Nathan PC (2010) Optimizing emetic control in children receiving antineoplastic therapy: Beyond the guidelines. Pediatr Drugs 12:51\u201361","journal-title":"Pediatr Drugs"},{"key":"7423_CR19","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW et al (2003) Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157\u20131167. https:\/\/doi.org\/10.1056\/NEJMra035092","journal-title":"N Engl J Med"},{"key":"7423_CR20","doi-asserted-by":"publisher","first-page":"122639","DOI":"10.1016\/j.jchromb.2021.122639","volume":"1171","author":"AL Nijstad","year":"2021","unstructured":"Nijstad AL, Tibben MM, Gebretensae A et al (2021) Development and validation of a combined liquid chromatography tandem-mass spectrometry assay for the quantification of aprepitant and dexamethasone in human plasma to support pharmacokinetic studies in pediatric patients. J Chromatogr B 1171:122639. https:\/\/doi.org\/10.1016\/j.jchromb.2021.122639","journal-title":"J Chromatogr B"},{"key":"7423_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/psp4.12611","volume":"10","author":"DJ Irby","year":"2021","unstructured":"Irby DJ, Ibrahim ME, Dauki AM et al (2021) Approaches to handling missing or \u201cproblematic\u201d pharmacology data: pharmacokinetics. CPT Pharmacometrics Syst Pharmacol 10:291\u2013308. https:\/\/doi.org\/10.1002\/psp4.12611","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"7423_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10928-020-09730-z","volume":"48","author":"W Krzyzanski","year":"2021","unstructured":"Krzyzanski W, Milad MA, Jobe AH et al (2021) Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. J Pharmacokinet Pharmacodyn 48:261\u2013272. https:\/\/doi.org\/10.1007\/s10928-020-09730-z","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"7423_CR23","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/BF02455994","volume":"32","author":"ME Brady","year":"1987","unstructured":"Brady ME, Sartiano GP, Rosenblum SL et al (1987) The pharmacokinetics of single high doses of dexamethasone in cancer patients. Eur J Clin Pharmacol 32:593\u2013596. https:\/\/doi.org\/10.1007\/BF02455994","journal-title":"Eur J Clin Pharmacol"},{"key":"7423_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/BF02280754","volume":"43","author":"SK Gupta","year":"1992","unstructured":"Gupta SK, Ritchie JC, Ellinwood EH et al (1992) Modeling the pharmacokinetics and pharmacodynamics of dexamethasone in depressed patients. Eur J Clin Pharmacol 43:51\u201355. https:\/\/doi.org\/10.1007\/BF02280754","journal-title":"Eur J Clin Pharmacol"},{"key":"7423_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/BF00614309","volume":"30","author":"D Loew","year":"1986","unstructured":"Loew D, Schuster O, Graul EH (1986) Dose-dependent pharmacokinetics of dexamethasone. Eur J Clin Pharmacol 30:225\u2013230. https:\/\/doi.org\/10.1007\/BF00614309","journal-title":"Eur J Clin Pharmacol"},{"key":"7423_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1126\/science.276.5309.122","volume":"276","author":"GB West","year":"1997","unstructured":"West GB, Brown JH, Enquist BJ (1997) A general model for the origin of allometric scaling laws in biology. Science 276:122\u2013126. https:\/\/doi.org\/10.1126\/science.276.5309.122","journal-title":"Science"},{"key":"7423_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/psp4.12404","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ (2019) NONMEM tutorial part I: description of commands and options, with simple examples of population analysis. CPT Pharmacometrics Syst Pharmacol 8:525\u2013537. https:\/\/doi.org\/10.1002\/psp4.12404","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"7423_CR28","doi-asserted-by":"publisher","unstructured":"Nijstad AL, de Vos-Kerkhof E, Enters-Weijnen CF, et al (2022) A simple extemporaneous oral suspension of aprepitant yields sufficient pharmacokinetic exposure in children. J Oncol Pharm Pract 107815522210892.\u00a0https:\/\/doi.org\/10.1177\/10781552221089243","DOI":"10.1177\/10781552221089243"},{"key":"7423_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1023\/A:1011543508731","volume":"28","author":"ADR Huitema","year":"2001","unstructured":"Huitema ADR, Math\u00f4t RAA, Tibben MM et al (2001) A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. J Pharmacokinet Pharmacodyn 28:211\u2013230. https:\/\/doi.org\/10.1023\/A:1011543508731","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"7423_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143\u2013151. https:\/\/doi.org\/10.1208\/s12248-011-9255-z","journal-title":"AAPS J"},{"key":"7423_CR31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10928-017-9542-0","volume":"44","author":"AG Dosne","year":"2017","unstructured":"Dosne AG, Bergstrand M, Karlsson MO (2017) An automated sampling importance resampling procedure for estimating parameter uncertainty. J Pharmacokinet Pharmacodyn 44:509\u2013520. https:\/\/doi.org\/10.1007\/s10928-017-9542-0","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"7423_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN)\u2013a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75:85\u201394. https:\/\/doi.org\/10.1016\/j.cmpb.2003.11.003","journal-title":"Comput Methods Programs Biomed"},{"key":"7423_CR33","doi-asserted-by":"publisher","unstructured":"Boeckmann AJ, Sheiner LB, Beal SL (2011) NONMEM User Guide. NONMEM Part V 2\u2013169.\u00a0https:\/\/doi.org\/10.1007\/s13398-014-0173-7.2","DOI":"10.1007\/s13398-014-0173-7.2"},{"key":"7423_CR34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","volume":"101","author":"RJ Keizer","year":"2011","unstructured":"Keizer RJ, van Benten M, Beijnen JH et al (2011) Pira\u00f1a and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed 101:72\u201379. https:\/\/doi.org\/10.1016\/j.cmpb.2010.04.018","journal-title":"Comput Methods Programs Biomed"},{"key":"7423_CR35","unstructured":"RC Team (2009) R: a language and environment for statistical computing. R Found Stat Comput Vienna"},{"key":"7423_CR36","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1200\/JCO.2007.13.8404","volume":"26","author":"L Yang","year":"2008","unstructured":"Yang L, Panetta JC, Cai X et al (2008) Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 26:1932\u20131939. https:\/\/doi.org\/10.1200\/JCO.2007.13.8404","journal-title":"J Clin Oncol"},{"key":"7423_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejca.2019.07.026","volume":"120","author":"RK Jackson","year":"2019","unstructured":"Jackson RK, Liebich M, Berry P et al (2019) Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia\u2014a report from the UKALL 2011 trial. Eur J Cancer 120:75\u201385. https:\/\/doi.org\/10.1016\/j.ejca.2019.07.026","journal-title":"Eur J Cancer"},{"key":"7423_CR38","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO Guideline Update. J Clin Oncol 38:2782\u20132797. https:\/\/doi.org\/10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"7423_CR39","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/pbc.25915","volume":"63","author":"P Patel","year":"2016","unstructured":"Patel P, Robinson PD, Orsey A et al (2016) Chemotherapy-induced nausea and vomiting prophylaxis: practice within the Children\u2019s Oncology Group. Pediatr Blood Cancer 63:887\u2013892. https:\/\/doi.org\/10.1002\/pbc.25915","journal-title":"Pediatr Blood Cancer"},{"key":"7423_CR40","doi-asserted-by":"publisher","unstructured":"Patel P, Olteanu A, Cabral S, et al (2020) Dexamethasone dosing for prevention of acute chemotherapy\u2010induced vomiting in pediatric patients: a systematic review. Pediatr Blood Cancer 67.\u00a0https:\/\/doi.org\/10.1002\/pbc.28716","DOI":"10.1002\/pbc.28716"},{"key":"7423_CR41","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1365-2125.2009.03591.x","volume":"70","author":"M Cella","year":"2010","unstructured":"Cella M, Knibbe C, Danhof M, Della Pasqua O (2010) What is the right dose for children? Br J Clin Pharmacol 70:597\u2013603. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03591.x","journal-title":"Br J Clin Pharmacol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07423-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07423-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07423-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:23:28Z","timestamp":1669901008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07423-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7423"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07423-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"5 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the institutional Medical Ethics Committee of the Erasmus MC (MEC-2018\u20131578).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}